Oncolytics Biotech® Inc. dina iki ngumumake publikasi data praklinis lan pasien babagan pelareorep ing jurnal Imunologi sing ditinjau peer. Makalah kasebut, kanthi irah-irahan "Perawatan virus onkolitik beda-beda mengaruhi subset sel CD56dim lan CD56bright NK ing vivo lan ngatur spektrum aktivitas sel NK manungsa," diterbitake kanthi kolaborasi karo peneliti ing sawetara institusi bergengsi, kalebu Sekolah Kedokteran Universitas Leeds lan Institut Riset Kanker, London. Link menyang kertas bisa ditemokake kanthi ngeklik kene.

Diterangake ing kertas kasebut yaiku studi in vitro ngevaluasi efek pelareorep ing sel Natural Killer (NK) uga analisa sampel getih saka pasien metastasis ati kolorektal sing dijupuk sadurunge lan sawise perawatan karo pelareorep. Asil nuduhake perawatan pelareorep nyebabake aktivasi sel NK, sing dikenal kanthi langsung mateni sel kanker nalika ngrangsang kekebalan anti-tumor adaptif. Efek sing bermanfaat saka pelareorep diamati ing sampel pasien lan in vitro lan ditengahi dening sinyal interferon tipe 1 (IFN-1), jalur kunci sing melu immunoregulasi lan pangenalan sel tumor.

"Asil penting iki luwih nuduhake mekanisme imunologik bawaan lan adaptif pelareorep, lan kita seneng bisa diterbitake ing jurnal sing prestisius lan ditinjau peer," ujare Dr. Matt Coffey, Presiden lan Kepala Eksekutif Oncolytics Biotech lan co-penulis saka kertas. "Nalika ndeleng temuan kasebut, bebarengan karo data klinis sadurunge sing nuduhake kemampuan pelareorep kanggo ngaktifake sel T nalika promosi infiltrasi menyang tumor, kita ndeleng pelareorep menehi respon imun anti-kanker sing kuat lan terkoordinasi sing didorong dening sistem kekebalan bawaan lan adaptif. Ing ngarep, kita bakal terus nggunakake efek imunoterapeutik saka pelareorep nalika kita terus ngembangake minangka teknologi sing bisa digunakake kanggo macem-macem agen immunotherapeutic ing kanker payudara lan indikasi onkologi liyane kanthi kabutuhan sing ora dikarepake.

Sampel pasien sing dievaluasi ing publikasi kasebut saka studi klinis jendela kesempatan sing rampung ngevaluasi pelareorep ing pasien kanker kolorektal kanthi metastase ati. Patients nampa antarane siji lan limang dosis saka pelareorep sadurunge ngrancang surgery kanggo resect metastases. Sampel getih dijupuk sadurunge lan ing sawetara wektu sawise perawatan pelareorep. Rincian tambahan babagan uji coba, uga asil sing dilaporake sadurunge, kasedhiya ing publikasi sing dideleng sadurunge.

APA sing kudu dijupuk saka ARTIKEL INI:

Described in the paper are in vitro studies evaluating pelareorep’s effects on Natural Killer (NK) cells as well as analyses of blood samples from patients with colorectal liver metastases taken prior to and after treatment with pelareorep.
The beneficial effects of pelareorep were observed both in patient samples and in vitro and were mediated by type 1 interferon (IFN-1) signaling, a key pathway involved in immunoregulation and tumor cell recognition.
Looking forward, we will continue to leverage the immunotherapeutic effects of pelareorep as we further its development as an enabling technology for a wide cross-section of immunotherapeutic agents in breast cancer and other oncologic indications with high unmet needs.